JP2020522524A5 - - Google Patents

Download PDF

Info

Publication number
JP2020522524A5
JP2020522524A5 JP2019566881A JP2019566881A JP2020522524A5 JP 2020522524 A5 JP2020522524 A5 JP 2020522524A5 JP 2019566881 A JP2019566881 A JP 2019566881A JP 2019566881 A JP2019566881 A JP 2019566881A JP 2020522524 A5 JP2020522524 A5 JP 2020522524A5
Authority
JP
Japan
Prior art keywords
asthma
antibody
pharmaceutical composition
eosinophil
severe
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019566881A
Other languages
English (en)
Japanese (ja)
Other versions
JP7295038B2 (ja
JP2020522524A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/031518 external-priority patent/WO2018226339A1/en
Publication of JP2020522524A publication Critical patent/JP2020522524A/ja
Publication of JP2020522524A5 publication Critical patent/JP2020522524A5/ja
Priority to JP2023094740A priority Critical patent/JP2023113883A/ja
Application granted granted Critical
Publication of JP7295038B2 publication Critical patent/JP7295038B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019566881A 2017-06-06 2018-05-08 小児患者のための生物薬剤組成物及び方法 Active JP7295038B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023094740A JP2023113883A (ja) 2017-06-06 2023-06-08 小児患者のための生物薬剤組成物及び方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762515641P 2017-06-06 2017-06-06
US62/515,641 2017-06-06
US201862619206P 2018-01-19 2018-01-19
US62/619,206 2018-01-19
PCT/US2018/031518 WO2018226339A1 (en) 2017-06-06 2018-05-08 Biopharmaceutical compositions and methods for pediatric patients

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023094740A Division JP2023113883A (ja) 2017-06-06 2023-06-08 小児患者のための生物薬剤組成物及び方法

Publications (3)

Publication Number Publication Date
JP2020522524A JP2020522524A (ja) 2020-07-30
JP2020522524A5 true JP2020522524A5 (https=) 2021-07-26
JP7295038B2 JP7295038B2 (ja) 2023-06-20

Family

ID=64566261

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019566881A Active JP7295038B2 (ja) 2017-06-06 2018-05-08 小児患者のための生物薬剤組成物及び方法
JP2023094740A Pending JP2023113883A (ja) 2017-06-06 2023-06-08 小児患者のための生物薬剤組成物及び方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023094740A Pending JP2023113883A (ja) 2017-06-06 2023-06-08 小児患者のための生物薬剤組成物及び方法

Country Status (7)

Country Link
US (2) US11390671B2 (https=)
EP (1) EP3634467A4 (https=)
JP (2) JP7295038B2 (https=)
CN (2) CN119632921A (https=)
BR (1) BR112019025736A2 (https=)
CA (1) CA3064859A1 (https=)
WO (1) WO2018226339A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019025736A2 (pt) * 2017-06-06 2020-06-30 Glaxosmithkline Llc uso de um anticorpo e composições para tratar uma doença e para diminuir uma contagem absoluta de eosinófilo no sangue
AU2020251627A1 (en) * 2019-03-29 2021-11-11 Jiangsu Hengrui Medicine Co., Ltd. Pharmaceutical composition containing antibody against IL-5 and use thereof
CA3199805A1 (en) * 2020-12-22 2022-06-30 Daren J AUSTIN Interleukin 5 binding protein dosage regimen

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8800397D0 (en) 1988-01-08 1988-02-10 Sandoz Ltd Improvements in/relating to organic compounds
AU633034B2 (en) 1988-11-03 1993-01-21 Schering Corporation Method of preventing or reducing eosinophilia
US5096704A (en) 1988-11-03 1992-03-17 Schering Corporation Method of treating eosinophilia
DE69309472T2 (de) 1992-01-23 1997-10-23 Merck Patent Gmbh, 64293 Darmstadt Fusionsproteine von monomeren und dimeren von antikörperfragmenten
HUT67943A (en) 1992-02-06 1995-05-29 Schering Corp Design, cloning and expression of humanized monoclonal antibodies against human interleukin-5
JPH06141885A (ja) 1992-11-05 1994-05-24 Chemo Sero Therapeut Res Inst モノクローナル抗体
GB9412230D0 (en) 1994-06-17 1994-08-10 Celltech Ltd Interleukin-5 specific recombiant antibodies
US7399837B2 (en) 1995-12-22 2008-07-15 Smithkline Beecham Corporation Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
US5693323A (en) 1994-12-23 1997-12-02 Smithkline Beecham Corporation Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
US5783184A (en) 1994-12-23 1998-07-21 Smithkline Beecham Corporation Method for treatment and diagnosis of IL-5 mediated disorders
US6248723B1 (en) 1997-06-10 2001-06-19 National Jewish Medical And Research Center Method for treatment of inflammatory disease
US5858089A (en) 1997-08-26 1999-01-12 Martinovic; Zoran Corn buttering tool
DE69838338T2 (de) 1997-10-22 2008-05-21 Jens Rochester Ponikau Verwendung von antimykotica zur topischen behandlung von pilz-induzierten schleimhautentzündungen
PT1527100E (pt) 2002-03-29 2009-08-25 Schering Corp Anticorpos monoclonais humanos para interleucina-5 e métodos e composições compreendendo os mesmos
JP4597643B2 (ja) 2004-11-24 2010-12-15 富士フイルム株式会社 電子内視鏡
DK2152290T3 (da) 2007-04-30 2014-08-18 Glaxosmithkline Llc Fremgangsmåder til indgivelse af anti-il-5-antistoffer
US20090035216A1 (en) 2007-08-03 2009-02-05 Biomonitor Aps Method for determining in vivo biopharmaceutical concentration or bioavailability
US20090148905A1 (en) * 2007-11-30 2009-06-11 Claire Ashman Antigen-binding constructs
JP5035153B2 (ja) 2008-07-14 2012-09-26 市光工業株式会社 車両用灯具
JP6125436B2 (ja) * 2011-02-09 2017-05-10 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ 凍結乾燥製剤
EA201391489A1 (ru) 2011-04-07 2014-02-28 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи Композиции со сниженной вязкостью
WO2014141149A1 (en) * 2013-03-15 2014-09-18 Glaxosmithkline Intellectual Property (No.2) Limited Formulations with reduced viscosity
KR20180037275A (ko) 2015-08-24 2018-04-11 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 생물제약 조성물
BR112019025736A2 (pt) * 2017-06-06 2020-06-30 Glaxosmithkline Llc uso de um anticorpo e composições para tratar uma doença e para diminuir uma contagem absoluta de eosinófilo no sangue

Similar Documents

Publication Publication Date Title
Wong et al. Omalizumab in the management of steroid dependent allergic bronchopulmonary aspergillosis (ABPA) complicating cystic fibrosis
JP2022543612A5 (https=)
JP2021523188A5 (https=)
JP2023527775A5 (https=)
JP2013543501A5 (https=)
Corren Anti-interleukin-5 antibody therapy in asthma and allerges
JP2020522524A5 (https=)
CN105451760A (zh) 使用贝那利珠单抗降低哮喘恶化率的方法
JP2002522503A (ja) 神経系障害を処置するための方法
McIvor Emerging therapeutic options for the treatment of patients with symptomatic asthma
JP2020100653A (ja) ベンラリツマブによる喘息症状の改善方法
EP4518970B1 (en) Use of myostatin inhibitor for treating spinal muscular atrophy
CN107073114A (zh) 使用瑞利珠单抗治疗中度到重度嗜酸细胞性哮喘
JP2024532263A5 (https=)
JP2018529766A5 (https=)
Wang et al. Biologics in pediatric psoriasis
Tello et al. Anti-interleukin-5 therapy (mepolizumab) in life-threatening asthma attack: A case-based discussion
JP2025506681A5 (https=)
Lucidi et al. A pilot trial on safety and efficacy of erythrocyte-mediated steroid treatment in CF patients
Passalacqua et al. Novel therapeutic interventions for allergic rhinitis
EP1067838A1 (en) Treatment of respiratory disease and otitis media
EP4587025A1 (en) Treating hiv with cabotegravir and rilpivirine in pediatric patients
Dasenbrook et al. Anti-inflammatory therapies for cystic fibrosis
CN114569623A (zh) 己酸羟孕酮在制备治疗间质性肺炎的药物中的用途
Lazarus et al. Glucocorticoid administration for Graves’ hyperthyroidism treated by radioiodine. A questionnaire survey among members of the European Thyroid Association